BellaSeno trials next generation breast implant technology

BellaSeno is a clinical-stage medical device company born in Queensland in 2015 and now expanded to Liepzig in Germany. They are developing a next generation fully resorbable breast implant for soft tissue reconstruction, which recently started clinical trials in Australia. We connect with BellaSeno’s Co-Founder & Chief Executive Officer Dr Mohit Chhaya and Chief Medical Officer Dr Tobias Grossner in Germany, to discuss their ground-breaking 3D printing technology that aims to restore breast tissue. In a global collaboration, their team has been working with Queensland’s Herston Biofabrication Institute. And Brisbane breast surgeon and Director of the Comprehensive Breast Cancer Institute, Professor Owen Ung, shares a clinicians view on the importance of this innovation for patients. Professor Ung is a principal investigator for a trial which began recently in Queensland.MTPConnect hosts are Caroline Duell, Director Media and Communications and Andrew Bowskill, Director of Stakeholder Engagement for Queensland.